Evidence map›Paper›PMID 37830451›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2023

Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset.

Marcus W Koch, Ester Moral, Luis Brieva, Jop Mostert, Eva Mm Strijbis, Jacynthe Comtois, Pavle Repovic, James D Bowen, Jerry S Wolinsky, Fred D Lublin and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00211887 (A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients With Relapsing-Remitting Multiple Sclerosis), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00211887 phase3completednot on this map

A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients With Relapsing-Remitting Multiple Sclerosis (CombiRx)

TypeinterventionalSponsorFred LublinRan2005 to 2013Enrolled1,008ConditionsRelapsing Remitting Multiple SclerosisArmsInterferon beta 1-a, glatiramer acetate, placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marcus W KochDepartments of Clinical Neurosciences and Community Health Sciences, University of Calgary, Calgary, AB, Canada.ORCID 0000-0001-9972-5092
Ester MoralDepartment of Neurology, Hospital Sant Joan Despí Moisès Broggi, Barcelona, Spain.
Luis BrievaNeuroimmunology Group, Department of Medicine, University of Lleida-IRBLleida, Lleida, Spain Department of Neurology, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
Jop MostertDepartment of Neurology, Rijnstate Hospital, Arnhem, The Netherlands.
Eva Mm StrijbisDepartment of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands.ORCID 0000-0001-6705-5864
Jacynthe ComtoisDepartment of Medicine, Neurology Service, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada.
Pavle RepovicMultiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA.
James D BowenMultiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA.ORCID 0000-0002-4258-250X
Jerry S WolinskyDepartment of Neurology, McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.ORCID 0000-0002-8197-2762
Fred D LublinDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Gary CutterDepartment of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-8455-980X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClinical relapses are the defining feature of relapsing forms of multiple sclerosis (MS), but relatively little is known about the time course of relapse recovery.

objectiveThe aim of this study was to investigate the time course of and patient factors associated with the speed and success of relapse recovery in people with relapsing-remitting MS (RRMS).

methodsUsing data from CombiRx, a large RRMS trial (clinicaltrials.gov identifier NCT00211887), we measured the time to recovery from the first on-trial relapse. We used Kaplan-Meier survival analyses and Cox regression models to investigate the association of patient factors with the time to unconfirmed and confirmed relapse recovery.

resultsCombiRx included 1008 participants. We investigated 240 relapses. Median time to relapse recovery was 111 days. Most recovery events took place within 1 year of relapse onset: 202 of 240 (84%) individuals recovered during follow-up, 161 of 202 (80%) by 180 days, and 189 of 202 (94%) by 365 days. Relapse severity was the only factor associated with relapse recovery.

conclusionRecovery from relapses takes place up to approximately 1 year after the event. Relapse severity, but no other patient factors, was associated with the speed of relapse recovery. Our findings inform clinical practice and trial design in RRMS.

Indexed as

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingChronic DiseaseHumansKaplan-Meier EstimateRecurrenceclinical trialmultiple sclerosisRelapsing–remittingsteroidstreatment response

Identifiers

PMID37830451
PMCPMC10687796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.